metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
versus docetaxel
	Tislelizumab
	RATIONALE 303 unpublished NCT03358875	RCT	mNSCLC - L2 - all population	Tislelizumab	Docetaxel	Patients With stage IIB or IV Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen	-/-	NA	no results	no results According to BeiGene, in the interim analysis, the study achieved the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

NCT03358875

RCT

mNSCLC - L2 - all population

Tislelizumab

Docetaxel

Patients With stage IIB or IV Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen

-/-

According to BeiGene, in the interim analysis, the study achieved the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel

Tislelizumab